This patent application illustrates a series of cyclic peptides inhibiting Interleukin-23 (IL-23), as represented by Formula I. These cyclic peptides exhibit significant therapeutic potential for treating diseases and disorders associated with IL-23 imbalance, with a particular focus on inflammatory bowel disease (IBD).